Drug
PTK787
PTK787 is a pharmaceutical drug with 5 clinical trials. Historical success rate of 60.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
60.0%
Based on 3 completed trials
Completion Rate
60%(3/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
2(40%)
Phase Distribution
Ph phase_1
3
60%
Ph phase_2
2
40%
Phase Distribution
3
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
2(40.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
60.0%
3 of 5 finished
Non-Completion Rate
40.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(3)
Terminated(2)
Detailed Status
Completed3
Terminated2
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
60.0%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (60.0%)
Phase 22 (40.0%)
Trials by Status
completed360%
terminated240%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_1
Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
NCT00268918
terminatedphase_1
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
NCT00216047
completedphase_2
Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate Cancer
NCT00134355
terminatedphase_2
PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma
NCT00511043
completedphase_1
Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
NCT00138632
Clinical Trials (5)
Showing 5 of 5 trials
NCT00268918Phase 1
Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
NCT00216047Phase 1
PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer
NCT00134355Phase 2
Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate Cancer
NCT00511043Phase 2
PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma
NCT00138632Phase 1
Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5